Harwin Peter Evan

Director, 10% Owner · CRESCENT BIOPHARMA, INC.

Every open-market stock purchase Harwin Peter Evan has reported to the SEC on Form 4 that met our signal bar, parsed straight from the filings. This page tracks where those buys landed inside insider clusters and how the prices paid compare to where the stock trades now.

Total bought
$29.3M
Open-market buys
3
Companies
2
Last buy
Dec 4, 2025

Where the buys stand today

  • CBIO
    CRESCENT BIOPHARMA, INC.

    One purchase totalling $18.2M at an average of $13.41 per share. See all insider buying in CBIO →

    Avg price paid
    $13.41
    Latest price
    —
    Market cap
    Unknown
  • ZBIO
    Zenas BioPharma, Inc.
    +55.3% vs price paid

    2 purchases totalling $11.1M at an average of $18.03 per share; the stock last traded at $28.00. See all insider buying in ZBIO →

    Avg price paid
    $18.03
    Latest price
    $28.00
    Market cap
    $1.8B

Cluster participation

Qualifying buys grouped with other insiders buying the same stock — the pattern this site exists to catch.

All reported buys

DateTickerSharesPriceValueFiling
Dec 4, 20251,360,000$13.41$18.2MSEC ↗
Oct 7, 2025
ZBIOcluster
316,219$19.00$6.0MSEC ↗
Sep 16, 2024
ZBIOcluster
300,000$17.00$5.1MSEC ↗

Follow new qualifying clusters involving Harwin Peter Evan or other insiders

Explore qualifying clusters from public SEC filings. Pro adds email and Telegram notifications after detection.

About this data

Figures are parsed from Harwin Peter Evan's Form 4 filings on SEC EDGAR (CIK 1663607) and cover open-market purchases (transaction code P) — grants, option exercises, and sales are excluded, which is why totals here can differ from raw filing counts. Every row links to its source document.

This page is informational and reflects public filing data. It is not investment advice.